Thompson Creek Progress Adds Upside, but Valuation Still Demands Caution

What happened

Centerra's Thompson Creek project is advancing with heavy capex largely complete and production expected to begin mid-2027, while molybdenum prices are nearly 70% above feasibility assumptions, materially boosting projected cash flow and NAV. This supports a cautious Buy rating from Seeking Alpha with 20-24% upside. However, the stock has already rallied 71% from recent lows and 133% over the past year, trading at roughly 38x earnings and well above a conservative DCF estimate of $7.21 per share. The latest DeepValue master report had rated Centerra a WAIT, citing thin margin of safety, but the Thompson Creek development directly addresses one of its key watch items: economic restart of molybdenum assets. Overall, the investment case is improving, but the current price likely already reflects much of this positive news.

Implication

Investors should view the Thompson Creek restart and elevated molybdenum prices as a meaningful positive that could extend mine life and diversify cash flows, supporting a higher intrinsic value than the earlier DCF suggested. However, with the stock already up 71% from recent lows and trading at ~38x earnings, much of this upside may be discounted. A disciplined approach would be to wait for a better entry point near the DCF anchor or clear confirmation of Thompson Creek's ramp-up and sustained moly prices. The net cash balance sheet and Tier-1 jurisdiction assets provide downside support, but asset concentration and cyclical volatility argue for a conservative valuation. Long-term holders with higher risk tolerance might hold a core position, but new money should be deployed only after a pullback or further operational clarity.

Thesis delta

The previous WAIT stance was based on valuation with the stock well above DCF and limited near-term growth visibility. The new information on Thompson Creek—capex nearly complete, production slated for mid-2027, and molybdenum prices 70% above feasibility—directly addresses the growth and moly restart watch items. This shifts the thesis from WAIT to a cautious BUY, but only at more reasonable prices, as the stock's 71% rally likely already incorporates much of the upside.